JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Aura Biosciences Inc (AURA – Research Report) today and set a price target of $21.00. The company’s shares opened today at $7.58.
According to TipRanks, Wolleben is an analyst with an average return of -9.2% and a 26.12% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Mirum Pharmaceuticals, and Altimmune.
Currently, the analyst consensus on Aura Biosciences Inc is a Strong Buy with an average price target of $26.33, which is a 247.36% upside from current levels. In a report released yesterday, Scotiabank also assigned a Buy rating to the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aura Biosciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.3 million. In comparison, last year the company had a GAAP net loss of $13.47 million
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aura Biosciences Inc (AURA) Company Description:
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
Read More on AURA:
- Aura Biosciences price target lowered to $20 from $23 at Scotiabank
- Aura Biosciences 11M share Spot Secondary priced at $9.00
- Aura Biosciences announces common stock offering, no amount given
- Aura Biosciences reports agreement from FDA under SPA for CoMpass trial
- Aura Biosciences names Jill Hopkins CMO, Mark Plavsic CTO
